Featured

BioInvent KOL Call on Relapsed or Refractory Non-Hodgkin’s Lymphoma – $116M Raise

October 12, 2021

With our proprietary distribution network, LifeSci hosted a total of 140 overall attendees, including institutional investors, sell-side analysts, bankers, high net worth investors, and strategics   What: KOL Call on BI-1206 for Relapsed or Refractory Non-Hodgkin’s Lymphoma When: January 28, 2021 Who: Dr. Martin Welschof, CEO Dr. Andres McAllister, CMO Dr. Björn Frendéus, CSO Dr.…

Read More